Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix

Revekka Harisi, József Dudás, Ferenc Tímár, Gábor Pogány, S. Paku, J. Tímár, I. Kovalszky, M. Szendrői, A. Jeney

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Osteosarcoma cells are involved in the remodeling of the extracellular matrix (ECM) that affects their growth, invasive and metastatic activities. The tumour ECM provided effective protection against chemotherapy agents in several previously studied malignancies. The current study examined the effects of doxorubicin on cells that were migrated into a 3-dimensional extracellular matrix gel (ECM-gel) in comparison with its effects on cells remaining in the monolayer compartment. A human osteosarcoma cell line (OSCORT) was treated with doxorubicin in monolayer culture for 4 or 24 hours, and then overlaid by ECM-gel for 24 hours. Tumour cells remaining in the monolayer were separated from the cells migrated into ECM-gel, and both of them were characterized. OSCORT cells migrated into ECM-gel showed elevated levels and activity of topoisomerase II, increased protein expression of β1 integrin and matrix metalloproteinase-9 activity. Doxorubicin treatment for 4 hours resulted in increased cytotoxicity in the monolayer compartment relative to the cells migrated into ECM-gel, whereas 24-hour treatment at a low concentration (0.01 μg/ml) showed an antimigratory effect. Different antiproliferative and antimigratory effects of doxorubicin treatment schedules warrant short-term, high-dose treatment for targeting the tumour growth, and long-term, low-dose treatment for targeting the invasion of osteosarcoma.

Original languageEnglish
Pages (from-to)805-813
Number of pages9
JournalAnticancer Research
Volume25
Issue number2 A
Publication statusPublished - Mar 2005

Fingerprint

Osteosarcoma
Doxorubicin
Extracellular Matrix
Gels
Neoplasms
Therapeutics
Type II DNA Topoisomerase
Matrix Metalloproteinase 9
Growth
Integrins
Appointments and Schedules
Drug Therapy
Cell Line
Proteins

Keywords

  • β1 integrin
  • Doxorubicin
  • Extracellular matrix
  • Matrix-metalloproteinase
  • Migration
  • Osteosarcoma
  • Proliferation
  • Topoisomerase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix. / Harisi, Revekka; Dudás, József; Tímár, Ferenc; Pogány, Gábor; Paku, S.; Tímár, J.; Kovalszky, I.; Szendrői, M.; Jeney, A.

In: Anticancer Research, Vol. 25, No. 2 A, 03.2005, p. 805-813.

Research output: Contribution to journalArticle

@article{355f946497b04b4096095ec32a61c7d3,
title = "Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix",
abstract = "Osteosarcoma cells are involved in the remodeling of the extracellular matrix (ECM) that affects their growth, invasive and metastatic activities. The tumour ECM provided effective protection against chemotherapy agents in several previously studied malignancies. The current study examined the effects of doxorubicin on cells that were migrated into a 3-dimensional extracellular matrix gel (ECM-gel) in comparison with its effects on cells remaining in the monolayer compartment. A human osteosarcoma cell line (OSCORT) was treated with doxorubicin in monolayer culture for 4 or 24 hours, and then overlaid by ECM-gel for 24 hours. Tumour cells remaining in the monolayer were separated from the cells migrated into ECM-gel, and both of them were characterized. OSCORT cells migrated into ECM-gel showed elevated levels and activity of topoisomerase II, increased protein expression of β1 integrin and matrix metalloproteinase-9 activity. Doxorubicin treatment for 4 hours resulted in increased cytotoxicity in the monolayer compartment relative to the cells migrated into ECM-gel, whereas 24-hour treatment at a low concentration (0.01 μg/ml) showed an antimigratory effect. Different antiproliferative and antimigratory effects of doxorubicin treatment schedules warrant short-term, high-dose treatment for targeting the tumour growth, and long-term, low-dose treatment for targeting the invasion of osteosarcoma.",
keywords = "β1 integrin, Doxorubicin, Extracellular matrix, Matrix-metalloproteinase, Migration, Osteosarcoma, Proliferation, Topoisomerase II",
author = "Revekka Harisi and J{\'o}zsef Dud{\'a}s and Ferenc T{\'i}m{\'a}r and G{\'a}bor Pog{\'a}ny and S. Paku and J. T{\'i}m{\'a}r and I. Kovalszky and M. Szendrői and A. Jeney",
year = "2005",
month = "3",
language = "English",
volume = "25",
pages = "805--813",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix

AU - Harisi, Revekka

AU - Dudás, József

AU - Tímár, Ferenc

AU - Pogány, Gábor

AU - Paku, S.

AU - Tímár, J.

AU - Kovalszky, I.

AU - Szendrői, M.

AU - Jeney, A.

PY - 2005/3

Y1 - 2005/3

N2 - Osteosarcoma cells are involved in the remodeling of the extracellular matrix (ECM) that affects their growth, invasive and metastatic activities. The tumour ECM provided effective protection against chemotherapy agents in several previously studied malignancies. The current study examined the effects of doxorubicin on cells that were migrated into a 3-dimensional extracellular matrix gel (ECM-gel) in comparison with its effects on cells remaining in the monolayer compartment. A human osteosarcoma cell line (OSCORT) was treated with doxorubicin in monolayer culture for 4 or 24 hours, and then overlaid by ECM-gel for 24 hours. Tumour cells remaining in the monolayer were separated from the cells migrated into ECM-gel, and both of them were characterized. OSCORT cells migrated into ECM-gel showed elevated levels and activity of topoisomerase II, increased protein expression of β1 integrin and matrix metalloproteinase-9 activity. Doxorubicin treatment for 4 hours resulted in increased cytotoxicity in the monolayer compartment relative to the cells migrated into ECM-gel, whereas 24-hour treatment at a low concentration (0.01 μg/ml) showed an antimigratory effect. Different antiproliferative and antimigratory effects of doxorubicin treatment schedules warrant short-term, high-dose treatment for targeting the tumour growth, and long-term, low-dose treatment for targeting the invasion of osteosarcoma.

AB - Osteosarcoma cells are involved in the remodeling of the extracellular matrix (ECM) that affects their growth, invasive and metastatic activities. The tumour ECM provided effective protection against chemotherapy agents in several previously studied malignancies. The current study examined the effects of doxorubicin on cells that were migrated into a 3-dimensional extracellular matrix gel (ECM-gel) in comparison with its effects on cells remaining in the monolayer compartment. A human osteosarcoma cell line (OSCORT) was treated with doxorubicin in monolayer culture for 4 or 24 hours, and then overlaid by ECM-gel for 24 hours. Tumour cells remaining in the monolayer were separated from the cells migrated into ECM-gel, and both of them were characterized. OSCORT cells migrated into ECM-gel showed elevated levels and activity of topoisomerase II, increased protein expression of β1 integrin and matrix metalloproteinase-9 activity. Doxorubicin treatment for 4 hours resulted in increased cytotoxicity in the monolayer compartment relative to the cells migrated into ECM-gel, whereas 24-hour treatment at a low concentration (0.01 μg/ml) showed an antimigratory effect. Different antiproliferative and antimigratory effects of doxorubicin treatment schedules warrant short-term, high-dose treatment for targeting the tumour growth, and long-term, low-dose treatment for targeting the invasion of osteosarcoma.

KW - β1 integrin

KW - Doxorubicin

KW - Extracellular matrix

KW - Matrix-metalloproteinase

KW - Migration

KW - Osteosarcoma

KW - Proliferation

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=17444427131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444427131&partnerID=8YFLogxK

M3 - Article

C2 - 15868912

AN - SCOPUS:17444427131

VL - 25

SP - 805

EP - 813

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -